Oral Presentation Selected for Circular RNA Nanocarrier Technology
Demonstrating the Potential for In Vivo CAR-T

Algenomics, a company specializing in the development of RNA-based gene therapies, announced on May 4 that it will participate in the 29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) to be held in Boston, USA, from May 11 to 15. The company plans to present a total of three studies, including one oral presentation and two poster presentations, introducing the research achievements of its independently developed circular RNA technology and its new anti-cancer gene therapy platform.

Algenomics Presents Research Achievements on Next-Generation Circular RNA and Anti-Cancer Gene Therapy Strategies at ASGCT in the US View original image

ASGCT is the world’s largest society in the field of gene and cell therapy, and its annual meeting, held every May, serves as a venue for sharing innovative technologies and the latest clinical results in gene and cell therapy. In the 2025 event, more than 8,000 participants registered and over 2,000 abstracts were submitted.


In the oral presentation, the company will introduce research on polymer nanocarriers that selectively deliver circular RNA to immune cells in the spleen when administered systemically. Algenomics’ circular RNA leaves no extraneous sequences and is characterized by excellent stability and sustained expression. Particularly, circular RNA has demonstrated potential as an in vivo CAR-T platform that generates CAR-T immunotherapy cells directly within the body, making it an area of great interest in both academia and industry.


The poster presentations will cover research on RNA structural engineering that enables the efficient self-circularization of long RNA sequences, which are typically difficult to circularize. Additionally, the company will present the development of a new anti-cancer gene therapy platform based on RNA trans-splicing enzymes, which can simultaneously express anti-cancer genes and immune checkpoint inhibitors specifically in cancer cells, thereby enhancing the efficacy of combination therapies.



CEO Lee Sungwook emphasized, "By presenting the latest research achievements at the ASGCT, where gene and cell researchers from around the world convene, we aim to highlight the distinctiveness and scalability of our circular RNA and RNA trans-splicing enzyme platforms on the international academic stage, and to prove their competitiveness as next-generation RNA therapeutics."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing